Home / Transcripts / NewLake Capital Partners, Inc. (NLCP) · November 6, 2025

NewLake Capital Partners, Inc. (NLCP) Earnings Call Transcript

November 6, 2025

OTC Pink Market US Real Estate Industrial REITs earnings 21 min

Earnings Call Speaker Segments

Valter Pinto executive
#1

Thanks, operator. Good morning, everyone, and welcome to NewLake Capital Partners' Third Quarter 2025 Earnings Conference Call. With me today are Gordon DuGan, our Chairman; Anthony Coniglio, President and Chief Executive Officer; and Lisa Meyer, Chief Financial Officer. Before we get started, I want to point out that some of what we say on today's call might be considered forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. A range of risks and uncertainties could cause actual results to differ materially. For a fuller discussion of those risks, please see our press release that went out yesterday, our Form 10-Q for the quarter ended September 30, 2025, and our other filings with the SEC. We'll also be talking about certain non-GAAP financial measures, including FFO and AFFO. You can find reconciliations to the most directly comparable GAAP measures in our earnings release. With that, I'll hand the call over to our Chairman, Mr. Gordon DuGan.

Gordon DuGan executive
#2

Thanks, Valter, and good morning to all of you. The financial results for our third quarter matched what we had anticipated, which speaks to the caliber of the investments made several years back and the rigorous underwriting discipline applied from the day the company was founded. Whenever feasible, we take a proactive stance on handling risk across our portfolio, as shown by the lease amendments with C3 that we announced, and likewise through our work with Curaleaf to move a dispensary asset during the prior quarter. Staying responsive to an evolving landscape is essential for managing risk and maximizing long-term shareholder value. As we have noted in earlier quarters, conditions in the cannabis sector stay challenging, with constrained access to capital, market growth that has slowed and regulatory uncertainty that persists. In light of these dynamics, we continue to be cautious about new investments in cannabis and are concentrating on keeping a strong balance sheet and maintaining our dividend coverage. On the federal side, we keep waiting for meaningful reform that would enhance the operating environment for these state legal businesses. Regrettably, the government shutdown that occurred recently and the political gridlock surrounding it have pushed progress on this front even further back. Although the timing is still unclear, we believe reform will happen in the end. And once it does, NewLake will be positioned well to gain. Until then, our focus stays on execution, backing our tenants and delivering long-term value to our shareholders. With that, I'll hand the call over to Anthony.

Anthony Coniglio executive
#3

Thanks, Gordon, and good morning to all of you. As Gordon said, the results we posted for the third quarter matched what we had expected. Our AFFO rose by over 2% compared with the third quarter of 2024, and the payout ratio for AFFO stood at 82%, which falls inside the 80% to 90% target range; every scheduled rent payment came in during the quarter, aside from the 2 AYR properties, where July's rent arrived in cash and the security deposit was used for August and September. Since then, we've taken back control of those AYR properties located in Pennsylvania and Nevada, finished the cleanout and prep work that was needed, and listed them on the market as the re-tenanting effort gets underway. On the whole, our portfolio is still in a strong place. Tenants accounting for roughly 50% of annual base rent turned in solid third quarter results this week. Curaleaf widened adjusted gross margins and produced more than $100 million in cash flow so far this year. Cresco posted positive cash flow, cut its debt, and finished a refinancing, while Trulieve achieved some of the industry's best gross margins, close to 60%, and produced more than $60 million of free cash flow in the quarter. Green Thumb likewise announced another profitable quarter, with $23 million of net income and $74 million of operating cash flow; even so, the wider cannabis sector is still difficult given the absence of federal reforms, and we stay focused on proactively managing risk and finding opportunities to make our portfolio stronger. One good instance, as Gordon noted, is the lease amendments we recently made with C3. Lisa will go into more detail. But to remind you, we talked in earlier quarters about how construction costs that ran higher than expected made the Hartford project far less appealing. We collaborated with the tenant on a fix that keeps our risk in check while preserving AFFO for our investors. That comes after a similar collaboration last quarter with Curaleaf, in which we worked alongside the tenant to move a dispensary asset. All told, this is the fifth occasion on which we've partnered with tenants to devise creative answers to their needs while bolstering our risk profile and boosting long-term shareholder value. Now to regulatory issues. State-level actions give us encouragement, but we're worried about federal reform's ongoing delays. The recent enlargement of the Texas medical marijuana program along with this week's election of a new governor in Virginia, which ought to bring about the long-awaited start of adult-use, are both strong illustrations of ongoing growth opportunities arising at the state level. Yet the cannabis industry's health stays stuck in a drawn-out holding pattern, waiting for meaningful federal reform. That absence of clarity keeps dragging on operator sentiment and capital formation. Given that setting, we remain focused on upholding our disciplined underwriting and conservative balance sheet while staying cautiously optimistic about the wider environment. Finally, before handing things to Lisa, I want to take up a question I've been hearing more often lately about whether we intend to diversify into real estate sectors beyond cannabis. We believe we have a fiduciary duty to look at every path toward building shareholder value over the long term, and yes, that means weighing possibilities outside of cannabis as well; we keep watching the wider real estate market on an ongoing basis to spot appealing investments, especially those where our know-how in underwriting heavily regulated special purpose properties can be put to work. That effort will carry on. Should a compelling opportunity come along that fits both our strategy and our risk tolerance, we will take it to the Board for review. On that note, I'll turn things over to Lisa, who will walk us through our financial results.

Lisa Meyer executive
#4

Thanks, Anthony, and good morning to everyone. During 2025's third quarter, total revenue from our portfolio came to $12.6 million, which is up 0.3% compared with the same period last year, showing how solidly the portfolio performed in a difficult environment. Among the main reasons for that rise is a full quarter of rental income from the 2 Cresco dispensaries that were acquired earlier this year. We didn't fund any improvements in the third quarter, but we did receive a full quarter of rental income tied to $1.2 million of improvements funded after September 30, 2024, at our cultivation facilities in Arizona and Connecticut. On top of that, annual rent escalators throughout the portfolio keep delivering steady revenue growth. Another factor working against those improvements was the empty space at our property in Fitchburg, Massachusetts, following Revolutionary Clinics' departure in July of 2025. As I noted earlier, in the quarter we drew on $505,000 in security deposits from AYR to cover rent for August and September at our Pottsville, Pennsylvania and Sparks, Nevada locations, after AYR ceased making rent payments beginning in August. When the quarter closed, approximately $408,000 in security deposits remained, and we subsequently directed that sum toward the unpaid October and November rents. Net income attributable to common shareholders for the three months ended September 30, 2025 came to $6.7 million, or $0.32 per diluted share, compared with $6.4 million, or $0.31 per diluted share, during the third quarter of 2024. On the call, we noted adjusted funds from operations climbed 2.4% compared with a year earlier, reaching $11 million, which works out to $0.52 per share. The main driver there was a reduction in general and administrative expenses. We also declared a third quarter 2025 cash dividend of $0.43 per share of common stock, equivalent to $1.72 on an annualized basis. That payment went out on October 15, 2025, to stockholders of record as of September 30, 2025. Our portfolio's earnings power keeps fully covering the dividend, with an AFFO payout ratio of 82%, which sits comfortably within our 80% to 90% target range. Looking at our balance sheet as of September 30, 2025, it remains one of the strongest in the industry. We hold $432 million in gross real estate assets, and our debt position is very conservative — debt to total gross assets sits at just 1.6%, and nothing comes due before May 2027. On the liquidity side, we have $106 million available, which includes $23.6 million in cash plus what's left under our $90 million revolving credit facility. That leaves us with plenty of room to execute our business strategy and boost earnings by continuing to put money into high-quality assets. Last, I want to touch briefly on the recent changes we made to our lease agreements with C3 Industries, which are described in our earnings release and Form 10-Q. What we've done here really comes down to how we work together with our tenants. With the Hartford lease now amended, both sides agreed to move forward with selling that asset, and there's a make-whole clause built in that accounts for what each of us has invested. Rent payments from C3 keep coming until the sale closes, and once that happens, some of those funds get shifted over to the Missouri lease. That additional rent stays put until such time as we contribute capital again alongside C3 — and under our ROFR rights, we get the first opportunity to do so. With all that covered, I'll turn it over to the operator, and we can start taking your questions.

Pablo Zuanic analyst
#5

So, in the 10-Q and the press release, you provided details regarding how AYR affected AFFO, and a portion of the deposits were used for October and November. Could you attempt to put a number on what the entire AYR impact would be by the first quarter of next year, assuming those properties stay empty? Also, please remind us about Revolutionary Clinics: did any rent or deposits show up in AFFO for the third quarter? If nothing did, and if some amount did appear, what would the full quarterly effect be by the fourth quarter?

Anthony Coniglio executive
#6

Yes. Thanks for asking, Pablo. I'll take Revolutionary Clinics first, then Lisa can cover AYR. Regarding Revolutionary Clinics, as you may remember, they remained in the facility throughout their receivership period, and they paid rent in cash, while the security deposit for that had actually been drawn on in earlier years when their economic troubles began. The agreement with the receiver therefore called for cash payments through the end of July; so no, under that arrangement there are no remaining security deposits left to draw on; and now Lisa, please go ahead and discuss AYR.

Lisa Meyer executive
#7

Right. Regarding AYR, during the earnings call we held previously, we shared that for the first quarter we expect the effect to come in at slightly above $0.035, perhaps $0.036.

Pablo Zuanic analyst
#8

Understood. And here's a comparable question regarding C3 — when you look at a complete quarter, how will rental income be affected?

Lisa Meyer executive
#9

We put that deal together in a way that keeps the effect on net income minimal. As such, we expect no drop in either net income or AFFO stemming from that deal.

Anthony Coniglio executive
#10

Pablo, one more thing on top of what was said — rent payments from them will keep coming in right up to the point when the building gets sold. After the sale happens, that revenue shifts across to the Missouri facility; therefore, looking at it through an AFFO lens, we won't see any negative effect from it.

Pablo Zuanic analyst
#11

Correct. There are a few additional ones I want to ask about, and I apologize if folks are waiting in line. Look, I mean, clearly, if anything else were going on with your other tenants, you'd let us know, correct? So I'll be cautious when it comes to asking about other tenants. Take PharmaCann, for instance — one of your tenants. I realize they're a smaller tenant within your portfolio, yet they've defaulted on leases with IIPR, and that's publicly available information. And then Cannabis is the business whose balance sheet is stretched. But I mean, clearly, both of them are current on your leases, right? And I'm sorry to pose this question, but based on what's publicly available, I view them as risky tenants. But again, what I'm asking is whether they're current, correct?

Anthony Coniglio executive
#12

Yes.

Pablo Zuanic analyst
#13

Alright. That one's pretty straightforward. Now, shifting gears — regarding Virginia possibly turning rec, Pennsylvania possibly turning rec, and Texas Medical, I realize those markets could grow; we just can't pinpoint exactly when that happens. Still, could you discuss how far ahead of time operators begin coming to you for talks, assuming that ends up helping your book and helping you earn AFFO? In the best case, are we still talking 1 year away, 2 years away? How would you put it?

Anthony Coniglio executive
#14

Yeah. If what you're asking about is really growth, then the growth can come both from states where you already operate and from those going through the expansion you just described. For a dispensary, I'd put that lead time at a quarter. For cultivation, the lead time ought to be 6 to 8 months. Looking at it broadly, I'd describe the industry as cautious — and I think that's appropriate — when it comes to big CapEx projects. So although we do see one or two cultivation deals here and there, I believe that for the foreseeable future, dispensaries plus smaller cultivation sites will make up most of what's available for sale leaseback in this sector.

Pablo Zuanic analyst
#15

Alright. So, Anthony, there's one final thing I'd like to ask you about — just this last item. Among all the chief executives in this sector, you're arguably among the most prominent when it comes to sharing views on where the industry is headed. And obviously I mean that as a compliment. Your observations about the business are quite considered. I'm curious to hear how you see things regarding what have been described as commitments from the President — specifically around rescheduling, the pledges he posted on social media ahead of the election, plus the implicit assurances concerning medical cannabis and hemp-derived CBD that came from sharing that Commonwealth project clip on social platforms last September. A number of us — myself included — believe several of those commitments, assuming that's what they are, somewhat contradict one another, which could slow things down and make them messier. Still, I'd love to get your perspective on how you interpret these commitments and how you expect it all to unfold. And once more, I'm being bold in raising this, since you've offered quite considered perspectives on such matters previously in different venues.

Anthony Coniglio executive
#16

Thank you for asking, and for the nice words. Indeed, everyone in this sector is now perched nervously, reacting to each remark, each post, each signal, attempting to determine the moment this reform arrives. Every one of those data points is encouraging and pushes things forward; that said, personally, I'd pull back and note that considering the polling numbers, considering how people feel across this nation, considering the political forces surrounding cannabis, my strong conviction is that reform will come. So the real issue becomes the timing of it. Another truth, I think: if my conviction that reform will come is strong, my conviction is equally strong that, politically speaking, no party treats this as a priority. Through the past few administrations, both parties have made that clear. So my belief is that this administration backs reform. My belief is that we'll see it happen. My belief is simply that nobody can determine when the political circumstances align with the legislative circumstances and the electoral schedule in a way that delivers the substantive reform this industry deserves and requires. Hopefully that addresses what you asked. So let me wrap up for you, Pablo, by putting it this way: optimistic over the long haul, yet I think our industry occasionally gets too worked up over too many of these separate statements. Together they form a mosaic of reform, but my view is none of it can be used to forecast the timing. And one further point — you brought up CBD. There's another point we should acknowledge, which is that products made from hemp have really reshaped this sector in a major way. So suppose that means a somewhat longer wait before federal reform arrives — if we're able to secure rules governing those hemp-derived items, something I doubt anyone ever meant to genuinely permit through the 2018 Farm Bill — then I'm fine with that extra wait, because it would let us do this properly and put the industry on a durable footing, one where the lasting advantages of reform are firmly established.

Anthony Coniglio executive
#17

Alright, thanks so much, everyone, for being here on today's call. We're grateful for all the backing you give us. With Thanksgiving coming up soon — it's really not long now — we feel thankful to have every one of you as investors in and advocates for our business, and we wish you a wonderful day.

Operator operator
#18

That brings an end to the call for today. At this point, feel free to hang up your phones. We appreciate everyone joining us, and we hope the rest of your day is great.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete NewLake Capital Partners, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to NewLake Capital Partners, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.